« Back
Home /
Anti-Human Anthrax Toxin Receptor (CT) (ATR) - 0.1 mg

Anti-Human Anthrax Toxin Receptor (CT) (ATR) - 0.1 mg

Item no.	LEIN-A287-0.1mg
Manufacturer	Leinco Technologies
Amount	0.1 mg
Quantity options	0.1 mg 20 ug
Category	Antibodies Immunohistochemistry Western Blot Primary Antibodies
Type	Antibody Primary
Applications	WB, IHC
Specific against	Human (Homo sapiens)
Host	Rabbit
Citations	1. Carson-Walter, E. B. et al. (2001) Can. Res. 61:6649 2. Bradley, K. A. et al. (2001) Nature 414:225 3. Molloy, S. et al. (1992) J. Biol. Chem. 267:16396 4. Duesbery, N. et al. (1998) Science 280:734
ECLASS 10.1	32160702
ECLASS 11.0	32160702
UNSPSC	12352203
Shipping Condition	Room temperature
Available
Manufacturer - Applications	IHC FFPE, WB
Manufacturer - Category	Primary Monoclonal Antibodies>Infectious Diseases
Manufacturer - Targets	Anthrax Toxin Receptor
Country of Origin	USA
Shipping Temperature	Next Day Ambient
Storage Conditions	This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at –20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Product Description	The Anthrax toxin receptor (ATR) was initially discovered as the tumor endothelial marker 8 (TEM8).1 This protein, which exists in three isoforms (36, 40, and 60 kDa), is highly expressed in tumor vessels as well as in the vasculature of developing embryos, suggesting that it may normally play a role in angiogenesis. However, it also acts as the receptor for anthrax toxin.2 Following the binding of this protein by the protective antigen (PA) of anthrax, PA is cleaved and heptamerizes to form the binding site for both edema factor (EF) and lethal factor (LF).3 This complex is then endocytosed by the cell; acidification in endosomes allows the release of EF and LF into the cytoplasm where they interfere with MAPK signaling and induce apoptosis.4
Background	The Anthrax toxin receptor (ATR) was initially discovered as the tumor endothelial marker 8 (TEM8).¹ This protein, which exists in three isoforms (36, 40, and 60 kDa), is highly expressed in tumor vessels as well as in the vasculature of developing embryos, suggesting that it may normally play a role in angiogenesis. However, it also acts as the receptor for anthrax toxin.² Following the binding of this protein by the protective antigen (PA) of anthrax, PA is cleaved and heptamerizes to form the binding site for both edema factor (EF) and lethal factor (LF).³ This complex is then endocytosed by the cell; acidification in endosomes allows the release of EF and LF into the cytoplasm where they interfere with MAPK signaling and induce apoptosis.⁴
PubMed	Anthrax Toxin Receptor
Manufacturer - Research Area	Infectious Disease
Manufacturer - Specificity	Rabbit Anti-Human Anthrax Toxin Receptor (ATR) recognizes an epitope near the C-terminus of Human, Mouse and Rat ATR. This polyclonal antibody was purified using affinity chromatography.
RRID	AB_2828090
Concentration	0.5 mg/ml
Formulation	This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Additional Information	Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

LEIN-A287-0.1mg-safety-datasheet.pdf